About IMMUNOTECH-B Company

The Group is a leading cellular immunotherapy biomedical company in China. It has focused on the development and commercialization of T-cell immunotherapy for the past 17 years. EAL - its core research product - is a multi-target cellular immunotherapy product. It has accumulated more than ten years of experience in clinical application and has shown curative effects on various cancers. Research related to EAL began in 2006, and the Group has improved cell culture systems and methods, and developed a proprietary technology platform with independent intellectual property rights for the production of EAL cells. The group selected prevention of recurrence of liver cancer after surgery as a clinical indication for the EAL clinical trial. The plan is to submit an application to commercialize EAL in the Chinese market after the clinical trial results have reached statistical significance. The company's product pipeline covers major categories of cellular immunotherapy products such as non-genetically modified and genetically modified products, as well as multi-target and single-target products. In addition to EAL, the main products under development include 6B11, CAR-T cell series, and TCR-T cell series. The core technical team consists of senior cancer immunologists, and is industry-forward-looking and sensitive. The R&D team structure covers early R&D, pre-clinical research, clinical research, and commercial production and management, enabling product development to advance rapidly. The company has also established the technical platform required for the development of cellular immunotherapy products, and has set up an organization and management platform for clinical trials.